Pathstone Holdings
BMRN icon

Pathstone Holdings’s BioMarin Pharmaceuticals BMRN Stock Holding History

Pathstone Holdings’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$531K Buy
9,273
+253
+3% +$13.9K ﹤0.01% 1839
2026
Q1 		$510K Sell
9,020
-456
-5% -$26.6K ﹤0.01% 1745
2025
Q4 		$563K Buy
9,476
+1,281
+16% +$69.7K ﹤0.01% 1701
2025
Q3 		$444K Sell
8,195
-276
-3% -$15.8K ﹤0.01% 1823
2025
Q2 		$466K Sell
8,471
-1,478
-15% -$87K ﹤0.01% 1751
2025
Q1 		$703K Buy
9,949
+77
+0.8% +$5.18K ﹤0.01% 1550
2024
Q4 		$649K Sell
9,872
-39
-0.4% -$2.61K ﹤0.01% 1614
2024
Q3 		$697K Hold
9,911
– – ﹤0.01% 1555
2024
Q2 		$816K Buy
9,911
+742
+8% +$61.8K ﹤0.01% 1434
2024
Q1 		$801K Buy
9,169
+1,855
+25% +$166K ﹤0.01% 1424
2023
Q4 		$705K Buy
+7,314
New +$647K ﹤0.01% 1294

Other funds holding BMRN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Pathstone Holdings's BMRN Position: Q2 2026 in Review

Pathstone Holdings increased its BioMarin Pharmaceuticals (BMRN) stake by 2.8% in Q2 2026, buying an estimated $13.9K and bringing the position to 9,273 shares worth $531K. The position accounts for ﹤0.01% of the portfolio, ranked #1839.

Pathstone Holdings first reported a position in BMRN in Q4 2023 and has held it in 11 quarters since. The position peaked at $816K in Q2 2024. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

  • Pathstone Holdings held 9,273 shares of BioMarin Pharmaceuticals worth $531K as of Q2 2026.
  • Pathstone Holdings bought 253 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $13.9K.
  • BioMarin Pharmaceuticals made up ﹤0.01% of Pathstone Holdings's portfolio in Q2 2026, its #1839 holding.
  • Pathstone Holdings first reported a position in BioMarin Pharmaceuticals in Q4 2023 and has held it in 11 quarters since.
  • Pathstone Holdings's BioMarin Pharmaceuticals position peaked at $816K in Q2 2024.
  • 565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Pathstone Holdings's 13F filing for Q2 2026, filed 13 Aug 2026.